Stocks Health care GENB
NASDAQ · Health careGenerate Biomedicines, Inc. (GENB)
At June 30, 2026 it held $135.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Generate Biomedicines, Inc.
- Net worth
- Generate Biomedicines, Inc. has a market value (market cap) of $1.8B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Generate Biomedicines, Inc. does
Generate Biomedicines, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GENB.
Earnings: every quarter and the next report date
Latest SEC filings
What Generate Biomedicines, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake (5% or more) SCHEDULE 13G
- August 26, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 38% to $6.3M versus the same quarter last year; diluted EPS -$0.52 versus -$1.94.
- August 6, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 18% to $7.2M versus the same quarter last year; diluted EPS -$1.07 versus -$1.62.
- May 7, 2026
- March 2, 2026
- February 27, 2026
Insider trades
What the people running Generate Biomedicines, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $200.7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 29, 2026 | Arnold FrancesDirector | Soldpre-planned (10b5-1) | 11,409 | $184.7K |
| September 1, 2026 | Arnold FrancesDirector | Soldpre-planned (10b5-1) | 1,000 | $16K |
| March 4, 2026 | Nally MichaelChief Executive Officer, Director | Bought | 20,000 | $240K |
| March 2, 2026 | Afeyan NoubarDirector, 10% owner | Exercised optionsindirect | 12,723,940 | - |
| March 2, 2026 | Afeyan NoubarDirector, 10% owner | Exercised optionsindirect | 13,702,224 | - |
| March 2, 2026 | Afeyan NoubarDirector, 10% owner | Exercised optionsindirect | 987,491 | - |
| March 2, 2026 | Afeyan NoubarDirector, 10% owner | Exercised optionsindirect | 2,777,752 | - |
| March 2, 2026 | Afeyan NoubarDirector, 10% owner | Exercised optionsindirect | 2,777,752 | - |
Who owns GENB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Afeyan Noubar13G, passive with 14 related filers | 48.9% | May 15, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.6% | November 5, 2026 |
| Nally Michael13G, passive | 5.2% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 86 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Flagship Pioneering, LLC | 62,673,117 | 0 |
| Fmr LLC | 5,221,599 | +1,004,075 |
| Capital World Investors | 4,215,632 | +211,483 |
| Braidwell LP | 3,283,844 | -309,155 |
| Norges Bank | 2,094,616 | new |
| ARCH Venture Management, LLC | 1,944,426 | 0 |
| HarbourVest Partners LLC | 1,722,210 | 0 |
| BlackRock, Inc. | 1,659,966 | new |
| Baker Bros. Advisors LP | 1,423,602 | 0 |
| Jpmorgan Chase & Co | 1,409,649 | -1,537,610 |
| Deep Track Capital, LP | 1,333,815 | new |
| ARK Investment Management LLC | 1,284,617 | +786,209 |
| Vanguard Capital Management LLC | 1,132,750 | +1,001,431 |
| Harvard Management Co Inc | 1,111,100 | 0 |
| Nvidia Corp | 833,325 | 0 |
| Davern Capital Partners, LP | 824,679 | +232,879 |
| Siren, L.L.C. | 736,104 | 0 |
| Geode Capital Management, LLC | 735,003 | +616,760 |
| State Street Corp | 526,565 | new |
| Affinity Asset Advisors, LLC | 400,000 | +50,000 |
Insiders
7 insiders reported holding 4,398,884 shares in total, about $62.2M at the last price.
| Holder | Shares |
|---|---|
| Nally MichaelChief Executive Officer, Director | 1,889,3611,316,654 held indirectly |
| Afeyan NoubarDirector, 10% owner | 1,562,5001,562,500 held indirectly |
| Bancel StephaneDirector | 724,160724,160 held indirectly |
| Arnold FrancesDirector | 220,063 |
| Mendillo Jane LDirector | 1,500 |
| Silvers JasonPresident & CFO | 1,0001,000 held indirectly |
| Grous BethChief People Officer | 300300 held indirectly |
Questions about GENB
What does Generate Biomedicines, Inc. do?
Generate Biomedicines, Inc. is a company in the Health care sector, listed on NASDAQ as GENB. Its shares trade on NASDAQ under the ticker GENB.
What is Generate Biomedicines, Inc.'s net worth?
Generate Biomedicines, Inc. has a market value (market cap) of $1.8B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Generate Biomedicines, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 5, 2026.
Similar companies
Compare GENB with
Follow GENB
Get an email when Generate Biomedicines, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Generate Biomedicines, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.